157 related articles for article (PubMed ID: 37649899)
1. Prolonged SARS-CoV-2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: A case report.
Kambe R; Sato M; Uehara D; Iizuka Y; Kakizaki S
Clin Case Rep; 2023 Sep; 11(9):e7861. PubMed ID: 37649899
[TBL] [Abstract][Full Text] [Related]
2. Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
Franceschini E; Pellegrino M; Todisco V; Dolci G; Bettelli F; Meschiari M; Bedini A; Fregni-Serpini G; Grottola A; Guaraldi G; Pecorari M; Sarti M; Luppi M; Perno CF; Mussini C
Infection; 2023 Oct; 51(5):1577-1581. PubMed ID: 37076752
[TBL] [Abstract][Full Text] [Related]
3. Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma.
Ueda Y; Asakura S; Wada S; Saito T; Yano T
Intern Med; 2022 Aug; 61(16):2523-2526. PubMed ID: 35650124
[TBL] [Abstract][Full Text] [Related]
4. Prolonged SARS-CoV-2 Infection and Organizing Pneumonia in a Patient with Follicular Lymphoma, Treated with Obinutuzumab-Challenging Recognition and Treatment.
Łyżwa E; Sobiecka M; Lewandowska K; Siemion-Szcześniak I; Barańska I; Klatt M; Langfort R; Szturmowicz M; Tomkowski W
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992402
[TBL] [Abstract][Full Text] [Related]
5. A case of prolonged COVID-19 treated with tixagevimab/cilgavimab.
Shimizu T; Shirasaki H; Okafuji K; Sawazaki A; Iwabuchi T; Matubayashi R
Respirol Case Rep; 2023 Mar; 11(3):e01099. PubMed ID: 36789174
[TBL] [Abstract][Full Text] [Related]
6. Acute acalculous cholecystitis following extended administration of nirmatrelvir/ritonavir for persistent SARS-CoV-2 infection.
Ito W; Fukumori T; Asaoka N; Imakita N; Nishimura T; Furukawa R; Nishihara Y; Fujikura H; Sekine T; Yamaguchi N; Hirata Y; Miyamoto S; Kanno T; Katano H; Suzuki T; Kasahara K
J Infect Chemother; 2024 Jul; 30(7):659-663. PubMed ID: 38184107
[TBL] [Abstract][Full Text] [Related]
7. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
8. Successful dual antiviral therapy with remdesivir and ensitrelvir in a case of prolonged COVID-19 following B-cell depleting immunotherapy for malignant lymphoma.
Jung S; Yagi Y; Fukushima K; Nishikawa Y; Tanaka M; Kobayashi T; Yajima K; Ajisawa A; Imamura A
IDCases; 2023; 34():e01890. PubMed ID: 37693339
[TBL] [Abstract][Full Text] [Related]
9. Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: A case report.
Arai T; Mukai S; Kazama R; Ogawa Y; Nishida K; Hatanaka K; Gohma I
J Infect Chemother; 2022 Jun; 28(6):810-813. PubMed ID: 35115239
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Ishio T; Tsukamoto S; Yokoyama E; Izumiyama K; Saito M; Muraki H; Kobayashi M; Mori A; Morioka M; Kondo T
Ann Hematol; 2023 Jun; 102(6):1421-1431. PubMed ID: 37041299
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine.
Kuriyama K; Kitamura Y; Tsuji T; Nishikawa R; Nagata H; Ohshiro M; Sugitani M; Hirakawa Y; Matsumoto Y; Iwai T; Uchiyama H
Curr Probl Cancer; 2022 Apr; 46(2):100813. PubMed ID: 34844771
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
Grigg A; Dyer MJ; Díaz MG; Dreyling M; Rule S; Lei G; Knapp A; Wassner-Fritsch E; Marlton P
Haematologica; 2017 Apr; 102(4):765-772. PubMed ID: 28011903
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
14. Coadministration with bendamustine restores the antitumor activity of obinutuzumab in obinutuzumab-resistant tumors.
Yamashita-Kashima Y; Yorozu K; Fujimura T; Kawasaki N; Kurasawa M; Yoshiura S; Harada N; Kondoh O; Yoshimura Y
Int J Hematol; 2022 Jun; 115(6):860-872. PubMed ID: 35301681
[TBL] [Abstract][Full Text] [Related]
15. Ensitrelvir eradicates persistent SARS-CoV-2 infection in a follicular lymphoma patient treated with anti-CD20 antibodies.
Sakamaki I; Negoro E; Iwasaki H; Yamauchi T
J Infect Chemother; 2024 Feb; 30(2):147-149. PubMed ID: 37690521
[TBL] [Abstract][Full Text] [Related]
16. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
[TBL] [Abstract][Full Text] [Related]
17. Front-line management of non-Hodgkin lymphoma in Australia. Part 1: follicular lymphoma.
Trotman J; Cheah CY; Marlton P; Opat S
Intern Med J; 2019 Apr; 49(4):422-433. PubMed ID: 30230156
[TBL] [Abstract][Full Text] [Related]
18. Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group.
Paszkiewicz-Kozik E; Hus I; Palka M; Dębowska M; Końska A; Kotarska M; Tyczyńska A; Joks M; Twardosz M; Giza A; Wąsik-Szczepanek E; Kalicińska E; Wiśniewska A; Morawska M; Lewicka B; Szymański M; Targoński Ł; Romejko-Jarosińska J; Drozd-Sokołowska J; Subocz E; Swoboda R; Długosz-Danecka M; Lech-Maranda E; Walewski J
Adv Clin Exp Med; 2023 Jan; 32(1):131-136. PubMed ID: 36603138
[TBL] [Abstract][Full Text] [Related]
19. Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.
Heger JM; Eichenauer DA; Kasper P; Böll B; Shimabukuro-Vornhagen A; Kochanek M
Eur J Haematol; 2019 Sep; 103(3):268-271. PubMed ID: 31211882
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
Haukaas FS; Ohna A; Krivasi T
Appl Health Econ Health Policy; 2018 Aug; 16(4):569-577. PubMed ID: 29923173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]